 |
|
|
|
 |
|
|
 Contact |  Print version |  PDF version |  Recommend company
|
| Generex Biotechnology Corporation |
33 Harbour Square, Suite 202
M5J 2G2 Toronto
Canada
|
|
Portrait
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMistT device. The Company's flagship product, oral insulin (Generex Oral-lynT), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in various stages of clinical development around the world.
Industrial Sectors
Additional information
Generex Biotechnology Corporation
Toronto, Canada
News
|
|
|
|
|
|
Top
